Imagine learning your child has a devastating condition that could have been managed—or even prevented—if only it had been caught earlier. This is the heartbreaking reality for many families, including those of children diagnosed with Spinal Muscular Atrophy (SMA), a rare but severe genetic disorder. But here's where it gets controversial: despite advancements in treatment, early diagnosis remains a critical challenge, leaving some parents feeling failed by the healthcare system. And this is the part most people miss—the window for intervention is shockingly small, and delays can lead to irreversible damage.
SMA is a progressive muscle-wasting disease that, if left untreated, can be fatal within two years. Yet, many families report waiting months for a diagnosis, even after raising concerns about their child’s symptoms. Take Dani-Rae Brown, for example, who was diagnosed at 12 months old—seven months after her first symptoms appeared. Her father, Charlie Brown, shared with BBC Radio Wales Breakfast that Dani’s condition deteriorated rapidly, leaving her reliant on a wheelchair and at constant risk of illness. “Had she been screened at birth and treated, potentially she could have been walking, running, playing—just a typical child,” he said. It’s a sentiment echoed by Samantha Williams, whose son Lucian was diagnosed at six weeks old, despite showing symptoms in the womb. She recalls being dismissed as an “over-protective mum,” a frustration shared by many parents whose concerns are overlooked.
The spotlight on SMA intensified recently when former Little Mix star Jesy Nelson revealed her twin daughters, born prematurely last May, have the condition. In an emotional Instagram video, Nelson described SMA as the “most severe muscular disease,” affecting every muscle in the body, from legs and arms to breathing and swallowing. Her daughters, Ocean Jade and Story Monroe, are now facing a future where they “probably never walk.”
Here’s the controversial part: The Welsh government, following advice from the UK National Screening Committee (UK NSC), does not currently recommend routine newborn screening for SMA. While the NHS offers a blood spot test for nine rare conditions at five days old, SMA is not on the list—unless a sibling has the condition. SMA UK, a charity supporting affected families, is campaigning to change this, arguing that early screening and treatment can dramatically improve outcomes. But the UK NSC’s 2018 review concluded there wasn’t enough evidence of cost-effectiveness or robust treatments at the time. A pilot screening programme was approved in 2025, but its rollout has been delayed due to logistical hurdles, leaving families in limbo.
Giles Lomax, CEO of SMA UK, emphasizes the urgency: “Timing is everything. Babies diagnosed and treated before symptoms appear have significantly better health outcomes. Once symptoms begin, the damage to motor neurons is irreversible.” With an estimated 47 babies born with SMA in the UK in 2024, the stakes couldn’t be higher. Yet, the question remains: Why are we still waiting for action?
Thought-provoking question for you: Should early screening for SMA be prioritized, even if it means reallocating resources from other areas? Or is the current approach justified until more evidence is available? Share your thoughts in the comments—this is a conversation that needs to happen.
